Perampanel for epilepsy: No proof of added benefit

(Institute for Quality and Efficiency in Health Care) In an early benefit assessment IQWiG examined whether perampanel offers an added benefit over the previous standard therapy in people with epileptic fits. However, no such added benefit can be derived from the dossier, because the manufacturer failed to present suitable data for the comparison with lamotrigine or topiramate.
Source: EurekAlert! - Medicine and Health - Category: Global & Universal Source Type: news